Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sky Pharma Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, ensuring that the current prosecution dialogue is concentrated with a single individual. The portfolio is also restricted to 1 distinct art unit, which limits the procedural variations the company might encounter across different patent office divisions. This concentration suggests that the company is focusing its intellectual property efforts on a specific technological domain.
The busiest examiner for this company is MEJIAS, SAMANTHA LEE, who is managing 1 pending office action. Because the total number of pending actions is 1, this examiner is responsible for the full scope of the company's current active prosecution. This singular focus allows the applicant to tailor their legal arguments specifically to the expectations of MEJIAS, SAMANTHA LEE. The alignment of 1 pending action with 1 art unit and 1 examiner creates a straightforward administrative path for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907626 | METHOD FOR SCREENING FOR, METHOD FOR PRODUCING, AND METHOD FOR DESIGNING DRUG ACTIVE INGREDIENTS | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17907626 | METHOD FOR SCREENING FOR, METHOD FOR PRODUCING, AND METHOD FOR DESIGNING DRUG ACTIVE INGREDIENTS | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | — | Pending | Sep 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSky Pharma Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samantha Lee Mejias has the most, with 1 of Sky Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
